Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).
Ezzat Elhassadi, MD
Advertisement
Articles by Ezzat Elhassadi, MD
Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses p53 expression and prognosis in mantle cell lymphoma (MCL).
Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).
Ezzat Elhassadi, MD, consultant hematologist, Haematology Services, University Hospital Waterford, discusses the outlook of patients with p53-mutated mantle cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Elhassadi Discusses the Outlook of Patients With p53-Mutated MCLPublished: June 19th 2019 | Updated:
Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCLPublished: June 22nd 2019 | Updated:
Dr. Elhassadi on the Relationship Between p53 Expression and Prognosis in MCLPublished: June 28th 2019 | Updated:
Dr. Elhassadi on the Subtypes of MCLPublished: July 10th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5